EDAP's HIFU Technology Highlighted At Three Prestigious U.S. Medical Conferences LYON, France, Feb. 15, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that Ablatherm ® -HIFU was featured in presentations at three major U.S.
EDAP TMS SA to Present at Roth 20th Annual OC Growth Stock Conference LYON, France, Feb. 13, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in high-intensity focused ultrasound (HIFU) for the treatment of prostate cancer, announced today that Marc Oczachowski, Chief Executive
Dr. Andrew Weil on Ablatherm-HIFU We are proud to announce that Dr. Andrew Weil, a well-known physician and author, recently spoke of the benefits associated with Ablatherm-HIFU minimally invasive, robotized technology. Please click on the below link to view Dr.
Record Fourth Quarter Revenue
Financial Highlights:
Full year revenues of Euro 22.2 million, up 10% year-over-year
Record fourth quarter revenue of Euro 7.0 million, up 43% year-over-year
Robust 42% full year revenue attributed to Ablatherm-HIFU
Ablatherm-HIFU RPP treatments increased 36% year-over-year; 40% from fourth quarter 2006
Approximately 3,400 Ablatherm-HIFU treatments worldwide for year, yielding 15,000 cumulative treatments at 176 clinical sites
Successful launch of integrated Sonolith I-Sys for the disintegration of urinary stones
EDAP Retains The Ruth Group as Investor Relations Counsel LYON, France, Jan. 24, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in High Intensity Focused Ultrasound treatment of prostate cancer, announced today that it has retained The Ruth Group as its investor relations